Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 49,900 shares, a drop of 55.6% from the September 30th total of 112,400 shares. Approximately 2.8% of the shares of the company are short sold. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 0.0 days.
Monopar Therapeutics Price Performance
MNPR stock traded down $15.73 during midday trading on Friday, hitting $16.93. The stock had a trading volume of 3,356,530 shares, compared to its average volume of 705,090. The business has a 50-day moving average of $4.87 and a two-hundred day moving average of $3.92. The firm has a market cap of $296.00 million, a price-to-earnings ratio of -32.56 and a beta of 1.26. Monopar Therapeutics has a 52-week low of $1.37 and a 52-week high of $38.50.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Research analysts predict that Monopar Therapeutics will post -1.93 earnings per share for the current year.
Analyst Ratings Changes
Several analysts have weighed in on MNPR shares. HC Wainwright upped their target price on shares of Monopar Therapeutics from $2.00 to $6.00 and gave the stock a "buy" rating in a research report on Wednesday, August 14th. Rodman & Renshaw assumed coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a "buy" rating and a $50.00 price objective on the stock.
Check Out Our Latest Research Report on MNPR
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
